Genetic Technologies Limited (GENE)

2,3200 +0,0200 (+0,87%) Alla chiusura: 04:00PM EDT

Genetic Technologies Limited

60-66 Hanover Street
Fitzroy, VIC 3065
Australia
61 3 8412 7000
https://genetype.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 60

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Simon Morriss	Chief Executive Officer	264,4k	N/D	N/D
Mr. Carl S. Stubbings BSc	Chief Commercial Officer	175,14k	N/D	N/D
Mr. Kevin Camilleri	Chief Executive Officer of EasyDNA	169,02k	N/D	N/D
Ms. Kathryn J. E. Andrews B.Com., C.P.A., M.A.I.C.D.	CFO & Company Secretary	N/D	N/D	1967
Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA	Consultant	120,36k	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Governance aziendale

L'ISS Governance QualityScore di Genetic Technologies Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.